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WTPs. For a WTP of $270,000, the P(CE) for the no screen option was .482 with the 
TRI distributions and .535 with our revised distributions. ConClusions: In this 
case, despite the criticism of triangular distributions generally, CEA results were 
not appreciably different qualitatively or quantitatively with the change to more 
accepted distributional assumptions. For an intervention with an ICER closer to 
the CE threshold, the importance may be greater.
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CoSt-EffECtivEnESS AnAlYSiS of PonAtinib in thE trEAtmEnt of 
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objeCtives: In CP-CML, there are few therapeutic options for highly-resistant 
patients (e.g. third line [3L] or beyond), who have a poor prognosis. Current treat-
ment options are tyrosine kinase inhibitors (TKIs) and allogeneic stem cell trans-
plantation (allo-SCT) for suitable patients. Efficacy of ponatinib, designed to inhibit 
the kinase activity of native BCR-ABL and all mutant variants, including T315I, was 
demonstrated in patients with highly-resistant CML in the pivotal phase II Ponatinib 
Ph+ ALL and CML Evaluation(PACE) trial. In the absence of head-to-head trials, an 
economic model employing a Swedish public healthcare perspective was developed 
to assess the cost-effectiveness of ponatinib for 3L treatment of CP-CML compared 
with current treatment options in Sweden. Methods: The cost-effectiveness 
model compares ponatinib, second-generation TKIs (dasatinib, nilotinib, bosutinib), 
and allo-SCT, with cost per life-years (LY) saved and cost per quality-adjusted life-
years (QALYs) gained as outcome measures, and a lifetime time horizon. Resource 
use includes study drugs, monitoring and follow-up, adverse events and allo-SCT 
procedure. Costs, based on current tariffs in Sweden, and benefits (LY and QALYs) 
projected based on 12-month treatment response, were discounted at 3%/year. 
We performed sensitivity analyses (SA) to identify parameters that most strongly 
influenced results. Clinical validity was evaluated by comparing model-generated 
survival estimates with relevant clinical data. Results: Over the patients’ life-
time, ponatinib provides an increase in LY of almost 7 years and a gain of almost 
4 QALYs compared with the next-best therapy, bosutinib. The incremental cost-
effectiveness ratios range from SEK78,044/QALY gained vs. allo-SCT to SEK351,702/
QALY gained vs. bosutinib. SA showed the model was robust to plausible changes 
in input parameters and had good face validity. ConClusions: This analysis sug-
gests that treating 3L CP-CML with ponatinib provides substantial clinical benefit 
as compared with current alternatives at a reasonable cost, from the perspective 
of the Swedish public healthcare system.
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objeCtives: Biologics are used for the treatment of inflammatory bowel diseases 
(IBDs), Crohn´s disease (CD) and Ulcerative colitis (UC), while their costs are signifi-
cant high. To allocate health spending efficiently, biologics for IBDs are an important 
target for cost-effectiveness analyses. The aim of this study was to systemically 
review the cost-effectiveness of biologics for IBDs and to evaluate the methodo-
logical quality of cost-effectiveness analyses. Methods: The literature search 
was performed to Medline (Ovid), Cochrane Library and SCOPUS in June 2014. The 
cost-utility analyses of biologics for IBDs in adults were included in the review. 
Biologics were compared with conventional medical treatment, another biologic 
treatment, placebo and surgery. Data extraction form was designed beforehand. 
All costs were converted to 2014 euro. The methodological quality of the included 
studies was assessed by Drummond´s checklist, Philips´ checklist and Consolidated 
Health Economic Evaluation Reporting Standards (CHEERS) guideline. Results: 
Of the 1828 references found in the literature search, 25 studies were included in 
the final review. The main causes affected the cost-effectiveness of the biologics 
are the activity of the disease, the duration of the biological treatment and the 
treatment strategy. Among patients refractory to conventional medical treatment 
(CMT) for IBD, incremental cost-effectiveness ratio (ICER) ranged from dominance 
to € 549,335 per Quality-Adjusted Life Year (QALY) compared with CMT. Adalimumab 
produced more frequently lower ICERs than infliximab in comparison with CMT 
for CD. When compared biologics with another biologic treatment for CD, ICER 
ranged from dominance to € 24,012,483/QALY. A study including both direct and 
indirect costs produced more favorable ICERs than studies including only direct 
costs. ConClusions: With a threshold of € 35,000/QALY, current evidence showed 
that biologics are cost-effective for the induction treatment of active and severe 
IBD. Biologics were not cost-effective for moderate IBD. Between biologics the cost-
effectiveness remains unclear.
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objeCtives: A cost-effectiveness analysis (CEA) has been performed, from an 
Italian public payer perspective, to compare the first advanced therapy medici-
nal product (ATMP) containing stem cells for the treatment of Limbal Stem Cell 
Deficiency (LSCD) with conservative treatment, a standard alternative pathway. 
LSCD is a rare condition characterized by the shortage of limbal stem cells in the 
eye resulting in corneal conjunctivalization, corneal opacity, visual impairment and 
even blindness. A medicinal product has been recently approved by EMA as the first 
treatment in moderate-severe LSCD due to chemical or physical burn. Methods: 
Efficacy data derive from a retrospective, case-series, non-randomized, non-con-
1SIHS Health Economics Consulting, Torino, Italy, 2ARIAD Pharmaceuticals Europe Sàrl, 
Epalinges, Switzerland, 3University Hospital of Wales, Cardiff, UK, 4ARIAD Pharmaceuticals, Inc., 
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objeCtives: Adults with Philadelphia chromosome-positive (Ph+) acute lympho-
blastic leukaemia (ALL) who develop resistance or intolerance to first- and second-
generation tyrosine-kinase inhibitors (TKIs) may be eligible for potentially curative 
allogeneic hematopoietic stem cell transplantation (alloHSCT) if remission of the 
disease is achieved. The third-generation TKI ponatinib has been shown to be safe 
and efficacious in TKI resistant and intolerant patients, with 47% achieving a major 
cytogenetic response (MCyR). Accordingly, ponatinib followed by alloHSCT in those 
who achieve MCyR represents a potential therapeutic alternative to best supportive 
care (BSC) with standard chemotherapy only. Methods: A Markov cohort model 
was constructed to assess the cost-effectiveness after dasatinib failure of ponatinib 
followed by alloHSCT in patients who achieve MCyR, versus BSC. Direct medical 
costs for ponatinib, BSC, alloHSCT, monitoring and follow-up, and adverse events 
were considered from the perspective of the UK National Health Service. Treatment 
outcomes were estimated from data for the Ph+ ALL patients in a phase 2 ponatinib 
trial (PACE), alloHSCT recipients in the LALA-94 trial, and a historical cohort receiv-
ing BSC. In the absence of valuations for Ph+ ALL health states, utilities for blast-
phase chronic myeloid leukaemia were used. Outcomes were evaluated in terms 
of life-years (LY) and quality-adjusted life-years (QALYs), and cost-effectiveness 
in terms of life-years gained (LYG) and QALYs gained. Results: Patients in the 
ponatinib plus alloHSCT arm had higher overall survival (4.14 versus 0.32 LY) and 
QALYs (2.57 versus 0.09) than BSC, at an increased cost (£88,553 versus £21,208). 
Incremental cost-effectiveness ratios were £17,700/LYG and £27,200/QALY gained 
relative to BSC. ConClusions: Given the assumptions and limitation of this 
analysis, our results suggest ponatinib may offer improved survival and health-
related quality-of-life by enabling patients with Ph+ ALL who have failed dasatinib 
to achieve remission and benefit from alloHSCT, at a moderate increase in cost 
compared with BSC.
PSY54
CoSt-EffECtivEnESS AnAlYSiS of romiPloStim for thE trEAtmEnt of 
Adult ChroniC immunE thromboCYtoPEniC PurPurA (itP) in brAzil
dos Santos RF1, Vargas-Valencia JJ2, Giannopoulou A3, Campioni M3
1Amgen, São Paulo, Brazil, 2Econopharma Consulting, Ciudad de México, Mexico, 3Amgen (Europe) 
GmbH, Zug, Switzerland
objeCtives: To assess the cost-effectiveness of romiplostim as treatment for 
adult ITP splenectomized patients with refractory disease or non-splenectomized 
patients with surgery contra-indication, in comparison with the use of Intravenous 
Immunoglobulin (IVIg) rescue therapy only, from the Brazilian private health 
care perspective. Methods: A cost per response model was developed. Overall 
response rates were derived from the romiplostim clinical trials (Kuter 2008) and 
were weighted by the proportion of patients splenectomized or not. The use of IVIg 
as rescue therapy in both arms was derived from Pullarkat, 2009. Treatment cost 
was calculated assuming drug wastage for an average patient weight of 72.4Kg and 
height of 170cm. Bleeding rates according to severity and site (gastrointestinal, 
intracranial and other) were estimated for patients without response considering 
data from Weitz, 2012. Resources and procedures used for the treatment of bleed-
ing events were based on a medical specialist group recommendation and costs 
were obtained from official Brazilian databases. Gynecological bleed was used as 
a proxy for costs of other inpatient bleeds. The analysis assumed 50% splenecto-
mized patients and was performed over a time horizon of 24 weeks. Results: The 
average cost per patient over 24 weeks was R$60,509 for romiplostim (including 
rescue therapy and bleeding events costs) and R$173,319 for IVIg. 83.2% and 7.1% 
of patients in the romiplostim and IVIg arm respectively achieved overall response, 
leading to a cost per response equal to R$72,727 for romiplostim compared with 
R$2,424,047 for IVIg as rescue therapy. ConClusions: The use of romiplostim in 
the treatment of ITP increases and maintains the platelet level of splenectomized 
and non-splenectomized patients and, at the same time, reduces the need of 
rescue therapy as IVIg. That generates cost savings and positions romiplostim as 
a dominant (less costly and more effective) strategy when compared with IVIg 
rescue therapy only.
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objeCtives: In 2009 Yoo and Grosse (Y/G) compared screening/no screening for 
CAH in a CEA, including a PSA using triangular distributions with minimum (MIN), 
mode and maximum (MAX) values for parameters. These distributions have been 
criticized for use in PSAs (Briggs et al). This research reproduces the Y/G analysis 
and then conducts a PSA with more appropriate distributional assumptions to 
evaluate potential bias from triangular distributions. Methods: We limited our 
reanalysis to a change in distributions to focus on the question of distributional 
sensitivity. For parameters in Y/G with symmetric triangular distributions (MIN 
and MAX values equidistant from their mean/mode), we used a normal distribu-
tion with the same mean and chose a Standard Error based on a 95% confidence 
interval defined by the MIN and MAX values of the triangular. For non-symmetric 
distributions, we fit a beta distribution to the triangular, keeping the means equal 
and ensuring that the tails of the distributions extended slightly beyond the MIN 
and MAX of the triangular. Results: We reproduced the Y/G deterministic ICER 
($292,841 vs. Y/G reported $292,000). We also reproduced the triangular distribu-
tion-based PSA ICER from Y/G (256,947 vs Y/G $255,700). In our revised PSA, our 
mean ICER was higher ($273,187), but the CEACs were nearly superimposable. For 
low Willingness to Pay (WTP) values, the probability of being cost-effective - P(CE) 
- was very similar between the two analyses. There was some divergence at higher 
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objeCtives: Comparative evaluation of the cost effectiveness of treatment of 
patients with acute craniocerebral injury (CCI) efficiency using two therapy schemes 
in Ukraine. Methods: “The cost-efficiency” method was used to carrying out the 
research. Analysis was based on the results of opened randomized trial on the 
efficacy of L-Lysine Aescinat in patients with craniocerebral injury, carried out 
in the department of anesthesiology and intensive care at Regional hospital in 
Dnepropetrovsk. The clinical trial involved 38 patients randomized to main and 
control group (each group contained 19 patients). Standard therapy (fentanyl, 
diazepam, tramadol, adrenaline, furosemide, mannitol) and injections of L-Lysine 
Aescinat were administrated in main group; only standard therapy was adminis-
trated in the control group. Treatment of patients was carried out during 7 days. 
Direct costs were taken into account for therapy course expenditures schemes 
studying. Drugs prices were taken from Morion`s information system (May, 2015). 
As an indicator of the effectiveness after treatment were considered the follow-
ing: decreasing of intracranial hypertension, degree of brain perifocal edema and 
degree of conscious disturbance (Glasgow Coma Scale). Results: The treatment 
efficiency in main group patients was 73,68 % and 15.79 % in controls. Treatment 
costs were € 55,86 and € 31,84 correspondingly. “The cost-efficiency” analysis 
demonstrated that CER in main group was € 75,81and CER in control group was € 
201,65. ConClusions: The “cost-efficiency” analysis showed the use of L-Lysine 
Aescinat in combination with standard therapy to be more effective and less expen-
sive for treatment of 1 patient with craniocerebral injury in Ukraine The obtained 
results of pharmacoeconomic analysis will allow to optimize the costs of disease 
treatment by a state, insurance companies and patients.
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objeCtives: Myelofibrosis (MF) is a rare and life-threatening myeloproliferative 
disorder characterized by progressive scarring of the bone marrow and a number 
of severely debilitating symptoms. The objective of this analysis was to estimate 
cost-effectiveness of ruxolitinib (RUX) in a treatment of MF patients compared with 
best available therapy (BAT) in Finland. Methods: Efficacy data from RUX pivotal 
trial COMFORT-II was used as the most relevant clinical evidence of RUX versus BAT. 
A survival-based decision model with health states On-Treatment, Off-Treatment 
and Dead was constructed. Transitions between the health states were determined 
by overall survival (OS) and treatment discontinuation collected in COMFORT-II. 
Treatment discontinuation was used a proxy for progression. The model was calcu-
lated as a cohort expected value analysis with each health state having associated 
costs and utilities. Costs for health states included drug acquisition costs and health 
care resource use (HRU) classified by MF risk status (high or intermediate-2) and 
leukemia. HRU estimates are based on patient level data (n= 88) from Auria Biobank, 
and utility values were based on a standard gamble study. Finnish health care payer 
perspective was employed. The time horizon in the base case was a lifetime with 3 % 
discounting for costs and outcomes. Results: Treatment with RUX produced 2.43 
incremental QALYs with the incremental cost of € 102,802 compared to BAT, resulting 
incremental cost-effectiveness ratio 42,367€ /QALY. Sensitivity analyses showed that 
the model was robust to changes in model inputs. The most impactful parameters 
were the disease management costs and the hazard ratio for OS. ConClusions: 
The results suggest that the improvements in OS provided by RUX translate into 
long term gains in QALYs with reasonable incremental costs. The use of robust real-
life data from Auria Biobank is beneficial in managing uncertainty that relates to 
assumptions and data inputs of the model.
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objeCtives: To assess the societal cost-effectiveness of manual therapy (MT) in 
comparison with physical therapy (PT) among Dutch sub-acute and chronic non-
specific neck pain patients. Methods: An economic evaluation was conducted 
alongside a 52-week randomized controlled trial (RCT). In this RCT, 181 patients were 
randomized to the MT group (n= 90; mainly receiving mobilization) and PT group 
(n= 91; mainly receiving exercise therapy). Clinical outcomes included perceived 
recovery (yes/no), functional status (continuous and clinically relevant improvement 
- yes/no), and quality-adjusted life-years (QALYs). Societal costs were measured 
using self-reported questionnaires at three, 7, 13, 26, 39, and 52 weeks. Missing 
data were handled using multiple imputation. Bootstrapping techniques were used 
to assess the uncertainty of the results. Results: After 52 weeks, there were no 
significant between-group differences in clinical outcomes. During follow-up, inter-
vention costs (€ -32; 95%CI:-54 to -10) and healthcare costs (€ -126; 95%CI:-235 to 
-32) were significantly lower in the MT group than in the PT group, whereas unpaid 
productivity costs were significantly higher (€ 186; 95%CI:19 to 557). Societal costs 
did not significantly differ between groups (€ -96; 95%CI:-1975 to 2022). For QALYs 
and clinically relevant improvement in functional status, the maximum probability 
of MT being cost-effective in comparison with PT was low (≤ 0.54). For perceived 
recovery and continuous improvement in functional status, results showed that a 
large amount of money must be paid per additional unit of effect to reach a reason-
able probability of cost-effectiveness. ConClusions: The findings indicate that 
MT was not cost-effective in comparison with PT in patients with sub-acute and 
chronic non-specific neck pain for perceived recovery, functional status, and QALYs.
trolled, multicenter clinical study in which patients have been treated with ex-
vivo expanded autologous human corneal epithelial cells containing stem cells. 
Symptoms like pain, photophobia and burning, together with visual impairment, 
contributed to assess quality of life associated with the condition, while Quality 
Adjusted Life Years (QALYs) have been used to compare the outcomes of the recent 
approved product with conservative management, in a comparable patient pool. 
The considered cost data have been obtained from Italian tariff nomenclature 
databases. Results: Patients treated with conservative management presented 
QALY values between 6.51 and 9.71, depending on LSCD severity, whereas treat-
ments with ATMP ensured to patients between 10.22 and 13.60 QALY, with a total 
utility gain between 3.71 and 4.60 QALYs (result being discounted by 3.5% yearly). 
As a result of this utility gain, the approved product would meet an ICER threshold 
of 40,000 € /QALY cost of around € 160,000 per treatment. ConClusions: Offering 
long-term, potentially life-long, effectiveness after single treatment, ATMP analyzed 
delivers cost reduction in the long term management of LSCD, despite higher initial 
costs compared to conservative approach. The CEA of the product demonstrated a 
significant gain in terms of QALYs, amortizing the initial outlay for the treatment.
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objeCtives: The aim of this study was to estimate the cost-effectiveness of lidocaine/
tetracaine patch versus lidocaine/prilocaine cream for topical anaesthesia before vas-
cular access. Methods: A decision analytic model comparing lidocaine/tetracaine 
patch versus lidocaine/prilocaine cream for topical anaesthesia before vascular access 
was constructed based on the current clinical practice in Egypt and was derived 
from published sources. The clinical parameters were derived from a double-blind, 
randomized, paired study. The utility of the health states was derived using the avail-
able published data. Direct medical costs were obtained from the Ministry of health 
tariff in Egypt. No discounting was performed. Probabilistic sensitivity analysis (PSA) 
was conducted. Results: The total quality-adjusted life-years (QALYs) of Lidocaine/
Tetracaine patch was estimated to be 0.914147, whereas that of the lidocaine/prilo-
caine was estimated to be 0.826098 (with a net difference of 0.088049 QALYs). The 
total costs for Lidocaine/Tetracaine and lidocaine/prilocaine were EGP 93.19 and EGP 
60.00 respectively (with a net difference of 33.19 EGP). Thus the incremental cost-
effectiveness ratio (ICER) for Lidocaine/Tetracaine was EGP 376.95 /quality-adjusted 
life year. Results from PSA indicate that Lidocaine/Tetracaine had an 100% chance 
of being cost-effective at our EGP 70,000 per QALY threshold. ConClusions: The 
present study concludes that Lidocaine/Tetracaine ( Heated Patch Delivery System) 
is cost effective option for topical anaesthesia before vascular access when compared 
with lidocaine/prilocaine (Cream) based on the threshold stated by world health 
organization (3xGDP/capita) for low and middle-income countries.
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objeCtives: This three-year, international, multicentre, longitudinal, obser-
vational, cost-effectiveness study named RaDiCEA (RareDisease &Cost-
EffectivenessAnalysis) will assess the economic evaluation (cost of illness - COI 
and cost-effectiveness analisys - CEA) of innovative therapies (i.e., anti IL-1 
agents), quality of life (QoL) and effects of the prevention of otherwise irreversible 
central nervous system, eye, ear, kidney, and cartilage damages of different treat-
ment strategies for cryopyrin-associated periodic syndromes (CAPS) of adults and 
children. Methods: A virtual time-cohort approach and a Markov model simu-
lating health states corresponding to different CAPS severity will be developed to 
assess the cost-effectiveness of either anti IL-1 agents or other than anti IL-1. Due 
to the lack of a CAPS-specific severity index/damage score, a linear combination 
of existing indexes and damage scores related to specific organs and systems will 
be used to rank patient’s health statu. Coefficients of the resulting function will be 
assigned following a top-down (Delphi) approach and an interim-ex post principal 
component analysis. The model quantifies resource utilization for patients’ care 
in the National Health Systems’ perspectives and a broader societal perspective. 
QoL will be evaluated using EQ-5D questionnaires. Robustness of outcomes wil 
be tested through univariate and probabilistic sensitivity analyses. Results: The 
RaDiCEA project will assess the long-term effectiveness of different potentially 
life-long treatment strategies and COI, while exploring the feasibility of a new 
CEA model to be generated from a rare disease (CAPS) observational study. The 
economic outcomes will be given as the number of years spent in each health 
state, the related yearly costs and QoL. ConClusions: The importance and nov-
elty of the model is twofold: i) in its application, adopting the cost-effectiveness 
approach for assessing the impact of CAPS therapies, and ii) in the methods, 
extending the analyses of the impact of CAPS therapies in reducing the speed of 
disease progression.
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